TY - JOUR T1 - <em>De novo</em> bronchiectasis in haematological malignancies: patient characteristics, risk factors and survival JF - ERJ Open Research JO - erjor DO - 10.1183/23120541.00166-2019 VL - 5 IS - 4 SP - 00166-2019 AU - Ricardo J. José AU - Jocelin Hall AU - Jeremy S. Brown Y1 - 2019/10/01 UR - http://openres.ersjournals.com/content/5/4/00166-2019.abstract N2 - Patients with haematological malignancies often develop secondary immunodeficiency and respiratory infections that could predispose towards bronchiectasis, and this is supported by case reports and a previous small case series of 22 patients [1–4]. To improve understanding of this association we performed a retrospective review of patients with clinically significant bronchiectasis (defined as radiological evidence of bronchiectasis plus chronic productive cough or recurrent respiratory tract infections requiring antibiotic therapy) and haematological malignancy attending our respiratory clinic at a UK teaching hospital between January 2014 and April 2018. Patients were investigated according to the British Thoracic Society guideline [5].Bronchiectasis occurs de novo in haematological malignancy and is associated with significant mortality and morbidity. Rituximab predisposes to IgG deficiency and survival time is significantly associated with age, FEV1 % and stem cell transplantation. http://bit.ly/2KZwCZt ER -